Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropyl-beta-cyclodextrin on Wistar rats: histopathologic analysis.
Indomethacin (IM) is a non-steroidal anti-inflammatory drug which inhibits prostaglandin biosynthesis. It is practically insoluble in water and has the capacity to induce gastric injury. Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) is an alkylated derivative of beta-CD with the capacity to form inclusion complexes with suitable molecules. IM is considered to form partial inclusion complexes with HP-beta-CD by enclosure of the p-chlorobenzoic part of the molecule in the cyclodextrin channel, reducing the adverse effects. The aim of this paper is to evaluate the gastric damage induced by the IM inclusion complex prepared by freeze-drying and spray-drying. A total of 135 Wistar rats weighing 224.4 +/- 62.5 g were put into 10 groups. They were allowed free access to water but were maintained fasted for 18 h before the first administration until the end of the experiment. IM acid-form, IM trihydrated-sodium-salt and IM-HP-beta-CD spray and freeze-dried, at normal and toxic doses, were administered through gastric cannula once/day for 3 days. Seventy-two hours after the first administration, the animals were sacrificed and the stomachs collected and prepared for morphological study by using the haematoxylin-eosin technique. Lesion indexes (rated 0/4) were developed and the type of injury was scored according to the severity of damage and the incidence of microscopic evidence of harm. Microscopic assessment demonstrated levels of injury with index one on 10-25%. The type of complexation method had different incidence but the same degree. The results show that IM inclusion complexation protects against gastric injury, reducing the incidence and the maximum degree of severity from 4 to 1, with a better performance of the spray-dried complex.
Ribeiro-Rama
A C
AC
Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Largo D Dinis, Coimbra, Portugal.
Figueiredo
Isabel Vitoria
IV
Veiga
F
F
Castel-Branco
M M
MM
Cabrita
A M S
AM
Caramona
M M
MM
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000143:Acids; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000633:toxicity*; D004339:Drug Compounding; D004353:Drug Evaluation, Preclinical; D005260:Female; D005612:Freeze Drying; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D007213:Indomethacin / Q000737:chemistry / Q000633:toxicity*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012492:Salts; D012995:Solubility; D013276:Stomach Ulcer / Q000139:chemically induced / Q000473:pathology*; D047392:beta-Cyclodextrins / Q000737:chemistry*
D000143:Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D012492:Salts; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D007213:Indomethacin